Dr. Reddy’s Laboratories Launches Innovative Migraine Management Device in European Markets

Services

FNO Stocks with CA Abhay

Equity Investment with CA Abhay

Equity Trading with CA Abhay

Stock Market Masterclass

Option Trading with CA Abhay

Dr. Reddy’s Laboratories Launches Innovative Migraine Management Device in European Markets

Team FS

12/Apr/2024

Key Points:

Breakthrough Migraine Solution: Dr. Reddy's Laboratories introduces Nerivio, a revolutionary drug-free migraine management device, in Germany. This wearable technology utilizes Remote Electrical Neuromodulation (REN) to provide acute and preventive treatment for migraine, catering to adults and adolescents.
Global Expansion: Following its European debut, Nerivio is set to enter South Africa, Spain, and the UK, offering relief to migraine sufferers worldwide. The device, already approved by the USFDA and CE-mark certified, represents a significant advancement in migraine therapy.
Addressing a Global Health Concern: With migraine affecting millions globally, including around 213 million in India alone, the launch of Nerivio underscores Dr. Reddy’s commitment to addressing this widespread health challenge. The device's accessibility and effectiveness offer hope to individuals seeking drug-free solutions for migraine relief.

Dr. Reddy’s Laboratories, a leading pharmaceutical company, has unveiled Nerivio, a groundbreaking migraine management device, in the European market through its subsidiary, betapharm. Utilizing Remote Electrical Neuromodulation (REN), Nerivio offers a drug-free approach to both acute and preventive treatment of migraine, catering to the needs of adults and adolescents aged 12 and above.

Global Rollout of Nerivio
After its successful launch in Germany, Nerivio is poised for introduction in South Africa, Spain, and the UK, marking a significant milestone in expanding access to advanced migraine therapy solutions. The device's USFDA approval and CE-mark certification validate its efficacy and safety standards, offering reassurance to patients seeking innovative migraine management options.

Addressing a Global Health Challenge
Migraine stands as a prevalent global health concern, impacting millions of individuals worldwide. In India alone, approximately 213 million people grapple with this condition, with women comprising 60% of sufferers. Recognizing the profound impact of migraine on individuals' quality of life, Dr. Reddy's commitment to launching Nerivio underscores its dedication to addressing this widespread health challenge and improving patient outcomes.

Also Read : Metropolis Healthcare Soars to New Heights on Stellar Q4 Performance

Empowering Patients with Technology
MV Ramana, Chief Executive Officer of Branded Markets (India and Emerging Markets) at Dr. Reddy’s, emphasizes the significance of Nerivio's launch in providing relief to migraine sufferers. Particularly notable is the device's application during the child-bearing age, offering a drug-free solution that addresses the unique challenges associated with managing migraine in this demographic. By leveraging technology and digital therapeutics, Nerivio empowers patients to take control of their migraine symptoms, distinguishing it as a pioneering solution in the realm of migraine management.

Conclusion
Dr. Reddy’s Laboratories' introduction of Nerivio marks a pivotal advancement in migraine therapy, offering patients a non-pharmacological solution that harnesses the power of technology. As the device makes its way into global markets, it holds the promise of providing much-needed relief to individuals grappling with the debilitating effects of migraine. With its innovative approach and commitment to improving patient well-being, Nerivio epitomizes the intersection of healthcare and technology, paving the way for a brighter future for migraine sufferers worldwide.

Also Read : Sun Pharma Faces Setback as USFDA Flags Dadra Facility: Shares Dip

Join our Telegram Channel and WhatsApp Channel for regular Updates.

Services

Dr. Reddy’s Laboratories Launches Innovative Migraine Management Device in European Markets

Related News